Daniel Soland - Director, Kalvista Pharmaceuticals, Inc

As of October 1, 2021


Daniel Soland Net Worth

  • Net worth is estimated to be at least $391.04K
  • Owns at least 10,000 units of Kalvista Pharmaceuticals, Inc stock

Daniel Soland Trading

  • Largest purchase of shares was 10,000 units , worth over $118.75K on September 30, 2019
  • In total has made about 3 transactions over 2 years
  • Usually trades in September, April and October, with the busiest year in 2019
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Daniel Soland Mailing Address

  • Mailing address is 4560 Horton Street,m/s R-422 Emeryville CA 94608 CA

Kalvista Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
T. Andrew Crockett 2021 $556,120 $458,799 - $1,281,708 $11,400 $2,308,027
T. Andrew Crockett 2020 $556,120 $229,400 - $1,163,160 $11,882 $1,960,562
T. Andrew Crockett 2019 $505,000 $353,500 - $2,418,444 $11,000 $3,287,944
Benjamin L. Palleiko 2021 $435,000 $261,000 - $747,663 $15,850 $1,459,513
Benjamin L. Palleiko 2020 $435,000 $156,600 - $581,580 $11,900 $1,185,080
Benjamin L. Palleiko 2019 $366,000 $192,150 $527,794 $994,555 $11,000 $2,091,499
Christopher M. Yea 2021 $420,000 $252,000 - $712,060 $25,341 $1,409,401
Christopher M. Yea 2020 $420,000 $117,600 - $480,773 $25,271 $1,094,044
Christopher M. Yea 2019 $341,093 $174,596 - $891,350 $20,466 $1,427,505
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1348911/000119312521249158/d191826ddef14a.htm

Kalvista Pharmaceuticals, Inc Insider Trading

  • The most recent transaction was 10,000 units sold on October 4, 2021 by Andrew Thomas Crockett worth over $171.84K
  • In the last 4 years, insiders at Kalvista Pharmaceuticals, Inc sold an estimated value of $75.17M and bought an estimated value of $43.76M
  • The most active traders are Andrew Thomas Crockett, CEO,  Christopher Yea, Chief Development Officer,  and Edward Feener, Chief Scientific Officer
  • Insider trading is most common in October, with the busiest year in 2019

KalVista Pharmaceuticals, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1